RxDoctor Payments Data

Dorothy Sassi, NP

Nurse Practitioner · Springfield, MANPI 1356389043

Payments from drug & device makers

$1,329in general payments, 2019–2025

Across 57 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$575
  • Takeda Pharmaceuticals U.S.A., Inc.$219
  • Johnson & Johnson$86
  • Boehringer Ingelheim$80
  • Phathom Pharmaceuticals, Inc.$71
  • Bristol Myers Squibb$63
  • plus $235 from 6 others

What the payments were for

  • Food & beverage$1,32099%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,329 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$57,520
Medicare patients
575
Services billed
700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab20$610,677
LinzessLinaclotide137$117,080
Humira(Cf) PenAdalimumab11$88,179
CreonLipase/Protease/Amylase29$65,199
Mesalamine66$55,668
TrulancePlecanatide30$16,559
Omeprazole674$12,720
MotegrityPrucalopride Succinate11$9,857
Ursodiol25$8,750
Pantoprazole Sodium322$7,480
Dicyclomine Hcl177$5,799
Esomeprazole Magnesium36$5,160
Budesonide EcBudesonide24$4,448
Sucralfate60$4,199
CholestyramineCholestyramine (With Sugar)37$4,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$86$610,67720 claims
AbbVieLinzess, Creon$575$182,280166 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$47$16,55930 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$219$9,85711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →